Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy-Reference-Cited by-同舟云学术

Cardiorespiratory Progression Over 5 Years and Role of Corticosteroids in Duchenne Muscular Dystrophy

Published:2020-10 Issue:4 Volume:158 Page:1606-1616
ISSN:0012-3692
Container-title:Chest
language:en
Short-container-title:Chest

Author:

Trucco Federica,Domingos Joana P.,Tay Chee Geap,Ridout Deborah,Maresh Kate,Munot Pinki,Sarkozy Anna,Robb Stephanie,Quinlivan Rosaline,Riley Mollie,Burch Michael,Fenton Matthew,Wallis Colin,Chan Elaine,Abel Francois,Manzur Adnan Y.,Muntoni Francesco

Funder

Muscular Dystrophy

University College London

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,Critical Care and Intensive Care Medicine,Pulmonary and Respiratory Medicine

Reference47 articles.

1. Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management;Birnkrant;Lancet Neurol,2018

2. Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy;McNally;Circulation,2015

3. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the Guideline Development Subcommittee of the American Academy of Neurology;Gloss;Neurology,2016

4. Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study;McDonald;Lancet,2018

5. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy;Schram;J Am Coll Cardiol,2013

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationship between growth and ambulation loss in Duchenne muscular dystrophy boys on steroids;European Journal of Neurology;2024-09-09

2. Corticosteroids for the treatment of Duchenne muscular dystrophy: a safety review;Expert Opinion on Drug Safety;2024-08-27

3. Observing the Clinical Course of Duchenne Muscular Dystrophy in Medicaid Real-World Healthcare Data;Advances in Therapy;2024-05-02

4. Survival among patients receiving eteplirsen for up to 8 years for the treatment of Duchenne muscular dystrophy and contextualization with natural history controls;Muscle & Nerve;2024-03-14

5. Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies – Developing Potential Treatments for the Entire Spectrum of Disease;Journal of Neuromuscular Diseases;2024-03-05